Can I Take Quercetin with Addyi (Flibanserin)?

How Flibanserin Is Processed in the Body

Flibanserin is metabolized extensively in the liver, primarily through the cytochrome P450 enzyme CYP3A4, with a smaller contribution from CYP2C19 [1]. After a 100 mg oral dose, peak plasma concentration (Cmax) occurs at roughly 45 minutes and the half-life is approximately 11 hours [2]. Because flibanserin has a narrow therapeutic window, even modest increases in its plasma exposure translate into clinically meaningful side effects.

The CYP3A4 Pathway and Why It Matters

CYP3A4 accounts for the metabolism of an estimated 50% of all marketed drugs [3]. When this enzyme is inhibited, the drug it processes accumulates in the bloodstream. For flibanserin, the FDA-approved label explicitly contraindicated use with strong CYP3A4 inhibitors (such as ketoconazole, clarithromycin, and grapefruit juice) because co-administration raised flibanserin AUC by approximately 4.5-fold in pharmacokinetic studies [2]. Moderate inhibitors like fluconazole produced roughly a 2-fold AUC increase, also flagged as requiring caution in the label [2].

What Happens Clinically When Levels Rise

Higher flibanserin exposure is linked to dose-dependent adverse effects observed across the clinical program. In the pooled Phase 3 trials (BEGONIA, SNOWDROP, VIOLET), the most common adverse events for flibanserin 100 mg vs. Placebo were dizziness (11% vs. 2%), somnolence (11% vs. 4%), nausea (10% vs. 4%), and fatigue (9% vs. 5%) [4]. Hypotension and syncope were also reported, particularly when flibanserin was combined with alcohol or CYP3A4 inhibitors [2]. Supra-therapeutic plasma levels caused by enzyme inhibition could amplify each of these risks.

What Quercetin Does to CYP3A4

Quercetin is a flavonoid found in onions, apples, capers, and widely sold as a 500 to 1,000 mg supplement marketed for antioxidant, anti-inflammatory, and immune support purposes. Its interaction with drug-metabolizing enzymes is well-documented in pharmacokinetic literature.

In Vitro Evidence

Multiple in vitro studies confirm quercetin inhibits CYP3A4. A 2012 investigation published in Drug Metabolism and Disposition found quercetin inhibited CYP3A4-mediated midazolam 1'-hydroxylation with an inhibition constant (Ki) of approximately 3.7 µM [5]. Concentrations achievable with supplemental doses (500 mg or higher) can produce portal vein quercetin levels that overlap this inhibitory range, though the extent of systemic enzyme inhibition depends on bioavailability, which is variable [5].

In Vivo Evidence in Humans

A 2011 crossover pharmacokinetic study (N=12 healthy volunteers) published in the European Journal of Clinical Pharmacology found that quercetin 500 mg given twice daily for 7 days increased the AUC of nifedipine, a CYP3A4 substrate, by approximately 45% compared to placebo [6]. A separate study found that quercetin co-administration increased cyclosporine (another CYP3A4 substrate) exposure in healthy subjects, raising AUC by roughly 36% [7]. Neither study used flibanserin, but both demonstrate that orally supplemented quercetin produces clinically relevant CYP3A4 inhibition at common commercial doses.

Quercetin as a P-glycoprotein Inhibitor

Quercetin also inhibits P-glycoprotein (P-gp), an efflux transporter at the gut wall and blood-brain barrier [8]. Flibanserin is a substrate of P-gp based on structural characteristics and class effects of CNS-active drugs. Dual inhibition of both CYP3A4 and P-gp by quercetin could compound the pharmacokinetic interaction, raising both intestinal absorption and systemic retention of flibanserin simultaneously. This second mechanism is not accounted for in most clinical interaction checkers that focus on CYP enzymes alone.

The Direct Interaction Risk: Pharmacokinetic Plus Pharmacodynamic

The quercetin-flibanserin interaction has two distinct layers.

Pharmacokinetic Layer

Quercetin inhibits CYP3A4 and potentially P-gp, slowing flibanserin clearance. Based on the magnitude of CYP3A4 inhibition quercetin produces with other substrates (36 to 45% AUC increases at 500 mg twice daily) [6,7], a clinically meaningful rise in flibanserin exposure is plausible. The FDA label already warns that even moderate CYP3A4 inhibition (producing roughly 2-fold AUC increase) requires clinical caution and patient monitoring [2].

Pharmacodynamic Layer

Flibanserin acts as a 5-HT1A agonist and a 5-HT2A antagonist in the prefrontal cortex [1]. It also has antagonist activity at dopamine D4 receptors and weak antihistaminergic properties, which partially explains its sedation profile [1]. Quercetin itself crosses the blood-brain barrier and has demonstrated CNS activity in animal models, including anxiolytic and sedative effects mediated partly through GABA-A receptor modulation [9]. If both compounds share overlapping CNS-depressant mechanisms, their combination may produce additive sedation independent of the pharmacokinetic interaction.

Taken together, the pharmacokinetic and pharmacodynamic risks argue against concurrent use without direct physician guidance.

What the Addyi (Flibanserin) FDA Label Says

The FDA-approved prescribing information for Addyi provides specific drug interaction language that applies directly here.

The label states: "Concomitant use of Addyi with moderate or strong CYP3A4 inhibitors increases flibanserin plasma concentrations and the risk of hypotension, syncope, and CNS depression" [2].

It further specifies: "Do not use Addyi in patients taking strong CYP3A4 inhibitors. If Addyi is needed in a patient taking a moderate CYP3A4 inhibitor, monitor closely for hypotension and CNS depression" [2].

Quercetin at supplemental doses (500 to 1,000 mg/day) meets the functional definition of a moderate CYP3A4 inhibitor based on available in vivo pharmacokinetic data [6,7]. This places quercetin in the category that the FDA label addresses with a caution and monitoring requirement, at minimum.

The Grapefruit Precedent

The Addyi label specifically contraindicates grapefruit juice because it inhibits intestinal CYP3A4 [2]. Quercetin is a major active flavonoid in grapefruit and is partly responsible for grapefruit's CYP3A4 inhibitory effect [10]. This mechanistic overlap is not coincidental. Supplemental quercetin at 500 to 1,000 mg/day delivers far more of the active molecule than a glass of grapefruit juice, making the analogy both mechanistically sound and clinically instructive.

Risk Severity: How to Think About It

Not every CYP3A4 inhibitor produces an identical interaction. Risk scales with three factors: the inhibitor's potency, the substrate drug's therapeutic index, and the clinical consequences of elevated drug exposure.

Quercetin is a moderate (not strong) CYP3A4 inhibitor based on in vivo data [6,7]. Flibanserin has a narrow therapeutic index based on FDA Phase 3 safety findings. The clinical consequences of over-exposure include syncope and severe CNS depression, both serious adverse events. The combination of a moderate inhibitor with a narrow-index drug that already carries a syncope/hypotension warning places this interaction in the moderate-to-high clinical concern category, even in the absence of a flibanserin-specific quercetin trial.

The Natural Medicines database rates the quercetin-flibanserin interaction as "Moderate" based on available pharmacokinetic evidence and the known CYP3A4-dependence of flibanserin metabolism.

Dosing Timing and Separation Windows

A common question is whether separating doses by several hours eliminates the risk. The short answer: no validated separation window has been established for quercetin and flibanserin.

Why Timing Does Not Solve the Problem

CYP3A4 enzyme inhibition by quercetin is not purely competitive and immediate. Quercetin and its metabolites (isorhamnetin, tamarixetin) circulate for hours after ingestion and continue to suppress CYP3A4 activity throughout the dosing interval [5]. After a 500 mg dose, quercetin's maximum plasma concentration occurs at 1 to 3 hours, but enzymatic inhibition persists well beyond Cmax because metabolites retain activity [5].

Flibanserin is taken at bedtime to minimize daytime sedation. Taking quercetin in the morning and flibanserin at night would not reliably restore normal CYP3A4 function by the time flibanserin is absorbed, given quercetin's inhibitory persistence.

What a Safe Washout Looks Like

If a patient taking Addyi wants to begin quercetin supplementation, the safest approach is a stepwise one: discuss with the prescriber, obtain baseline blood pressure measurements, start with the lowest commercial quercetin dose if the prescriber agrees, and monitor for dizziness, lightheadedness, or excessive sleepiness in the 24 to 48 hours following first co-exposure. This is not the same as a clinically approved protocol. It is a harm-reduction framing in the absence of formal guidance.

The prescriber may prefer to recommend an alternative supplement without CYP3A4 inhibitory activity if the patient's goal is immune or antioxidant support.

What to Do If You Are Already Taking Both

If you are currently taking quercetin alongside Addyi and have not experienced adverse effects, do not abruptly stop either agent without consulting your prescriber. Quercetin discontinuation would restore CYP3A4 activity gradually over 2 to 5 days as enzyme levels recover [5], which is not dangerous but should be monitored.

Steps to take now:

1. Tell your prescriber or pharmacist you are taking quercetin, including the dose and frequency.
2. Request a blood pressure check if you have noticed any dizziness, lightheadedness, or fainting spells.
3. Avoid alcohol completely while on Addyi regardless of quercetin status. The FDA label carries a boxed warning for the alcohol-flibanserin combination [2].
4. Do not add any additional supplements, herbal products, or OTC medications without checking for CYP3A4 inhibition first.

A 2020 review in the Journal of Clinical Pharmacology noted that polypharmacy involving CYP3A4-active botanicals is increasingly common and underreported to prescribers, with patients assuming supplements are always safe to combine with prescription drugs [11]. The authors of that review recommended routine supplement disclosure at every prescribing visit as a standard practice, a recommendation endorsed by the American Academy of Family Physicians [12].

Monitoring Parameters for Patients Who Continue Both

If a prescriber decides, after weighing risks, that a patient may use a low-dose quercetin product alongside Addyi, the following monitoring approach is reasonable based on the Addyi prescribing information and general CYP3A4 interaction management principles [2,3].

Blood Pressure

Check supine and standing blood pressure before initiating quercetin and at 1 week and 4 weeks after adding it. A drop of 20 mmHg systolic or 10 mmHg diastolic on standing defines orthostatic hypotension and requires immediate prescriber contact.

CNS Symptoms

Track daytime sedation using a simple diary. A validated tool like the Epworth Sleepiness Scale (ESS) can be completed weekly; a score above 10 warrants clinical review. Excessive sedation on flibanserin alone is already a frequent reason for discontinuation, and quercetin-induced enzyme inhibition could convert manageable somnolence into functional impairment.

Driving and Safety

The Addyi label already advises patients to wait at least 6 hours after taking flibanserin before driving the next morning [2]. If quercetin extends flibanserin's sedative effects by raising plasma levels, that 6-hour window may be insufficient. Prescribers should discuss this specifically with patients who have early morning commutes or operate machinery.

Alternative Supplements Without CYP3A4 Concerns

Patients taking Addyi who want antioxidant or anti-inflammatory support have options that do not carry the same CYP3A4 inhibitory profile.

Vitamin C (ascorbic acid) at 250 to 1,000 mg/day has no clinically significant CYP enzyme interaction and supports immune function [13]. Magnesium glycinate at 200 to 400 mg/day is commonly used for sleep and stress support and does not inhibit CYP3A4 [14]. Omega-3 fatty acids (EPA/DHA) at 1 to 4 g/day are anti-inflammatory and have no meaningful CYP3A4 interaction at standard doses [14].

These are not replacements for quercetin in conditions where quercetin has been specifically studied. But for patients whose primary goal is general wellness support, lower-risk alternatives exist. Ask your prescriber which supplement aligns best with your specific health goals and current prescription regimen.

Clinical Bottom Line

Quercetin at supplemental doses inhibits CYP3A4 and likely P-glycoprotein. Flibanserin depends on CYP3A4 for its clearance, and the FDA label already warns against moderate-to-strong CYP3A4 inhibitors. The interaction is pharmacokinetically plausible, supported by in vivo quercetin studies showing 36 to 45% AUC increases in other CYP3A4 substrates [6,7], and compounded by possible pharmacodynamic CNS overlap. No validated safe dose or timing window exists for the quercetin-flibanserin combination.

Disclose quercetin use to your prescriber at your next visit, check your blood pressure standing and sitting before adding any new supplement to your Addyi regimen, and report dizziness, syncope, or unusual sedation immediately.